SCHEMBL1333784

SCHEMBL1333784

CCC(C)CCCCCCCCCCCCCCCCCCCCC(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 2/20 0.57
FFAR1 O14842 2/20 0.57
ALDH1A1 P00352 3/20 0.55
GPR84 Q9NQS5 7/20 0.54
PPARG P37231 7/20 0.54
PPARD Q03181 7/20 0.54
PPARA Q07869 7/20 0.54
HDAC11 Q96DB2 5/20 0.54
TSHR P16473 5/20 0.54
PTPN1 P18031 3/20 0.54
TLR2 O60603 2/20 0.54
TDP1 Q9NUW8 2/20 0.54
FABP4 P15090 2/20 0.54
SLC22A6 Q4U2R8 1/20 0.54
SLC22A8 Q8TCC7 1/20 0.54
MEN1 O00255 1/20 0.54
ESR1 P03372 1/20 0.54
ALOX15 P16050 1/20 0.54
PDE4A P27815 1/20 0.54
KMT2A Q03164 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2575619 1.00 FFAR4 (0.57) FFAR4FFAR1ALDH1A1GPR84PPARG
SCHEMBL2345376 1.00 FFAR4 (0.57) FFAR4FFAR1ALDH1A1GPR84PPARG
SCHEMBL336842 1.00 FFAR4 (0.57) FFAR4FFAR1ALDH1A1GPR84PPARG
SCHEMBL4285232 1.00 FFAR4 (0.57) FFAR4FFAR1ALDH1A1GPR84PPARG
SCHEMBL347119 1.00 FFAR4 (0.57) FFAR4FFAR1ALDH1A1GPR84PPARG
SCHEMBL2483372 1.00 FFAR4 (0.57) FFAR4FFAR1ALDH1A1GPR84PPARG
SCHEMBL22612557 1.00 FFAR4 (0.57) FFAR4FFAR1ALDH1A1GPR84PPARG
SCHEMBL22612553 1.00 FFAR4 (0.57) FFAR4FFAR1ALDH1A1GPR84PPARG
SCHEMBL22612525 1.00 FFAR4 (0.57) FFAR4FFAR1ALDH1A1GPR84PPARG
SCHEMBL346960 1.00 FFAR4 (0.57) FFAR4FFAR1ALDH1A1GPR84PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4294375-A1 METHODS OF LOADING EXTRACELLULAR VESICLES Lonza Sales AG (CH) 2023-12-27 EP claimed
US-20220354963-A1 EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF CODIAK BIOSCIENCES, INC. (US) 2022-11-10 US claimed
WO-2022178147-A1 METHODS OF LOADING EXTRACELLULAR VESICLES CODIAK BIOSCIENCES, INC. (US) 2022-08-25 WO claimed
CN-114728078-A Extracellular vesicles linked to molecules and uses thereof 科迪亚克生物科学公司 2022-07-08 CN claimed
EP-4013457-A1 EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF Codiak BioSciences, Inc. (US) 2022-06-22 EP claimed
WO-2021030777-A1 EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF CODIAK BIOSCIENCES, INC. (US) 2021-02-18 WO claimed
EP-2120586-B1 ADJUVANTS AND METHODS OF USING THEM ARCHER DANIELS MIDLAND CO (US) 2018-07-04 EP claimed
US-20160324150-A1 ADJUVANTS AND METHODS OF USING THEM ARCHER DANIELS MIDLAND COMPANY 2016-11-10 US claimed
US-9416065-B2 Adjuvants and methods of using them ARCHER DANIELS MIDLAND COMPANY (US) 2016-08-16 US claimed
US-9283442-B2 Golf ball DUNLOP SPORTS CO. LTD. (JP) 2016-03-15 US claimed
US-8425784-B2 Ozonolysis reactions in liquid CO2 and CO2-expanded solvents UNIVERSITY OF KANSAS (US) 2013-04-23 US claimed
EP-2120586-A2 ADJUVANTS AND METHODS OF USING THEM Archer-Daniels-Midland Company (US) 2009-11-25 EP claimed
WO-2008100896-A2 ADJUVANTS AND METHODS OF USING THEM ARCHER-DANIELS-MIDLAND COMPANY (US) 2008-08-21 WO claimed
US-20080194410-A1 acidificers propionic acid, methyl acetic acid, acetic acid, lactic acid, fumaric acid, citric acid, phosphoric acid mixed with lecithin emulsifier; nonphenolic nonionic surfactant such as ethoxylated monolycerides, fatty acid ethoxylates, polyoxyethylene alkyl ethers, polyoxyethylene alkyl esters; water ARCHER DANIELS MIDLAND COMPANY 2008-08-14 US claimed
US-12611415-B2 Methods and compounds for treatment of metabolic disease MONASH UNIVERSITY (AU) 2026-04-28 US disclosed
US-12594339-B2 Lipid prodrugs of JAK inhibitors and uses thereof SEAPORT THERAPEUTICS, INC. (US) 2026-04-07 US disclosed
EP-4294375-B1 METHODS OF LOADING EXTRACELLULAR VESICLES LONZA SALES AG (CH) 2026-04-01 EP disclosed
US-5219733-A Reacting sterol or fatty alcohol with fatty acid or ester in contact with microorganism-derived lipase in water or mixture of water and organic solvent YOSHIKAWA OIL & FAT CO., LTD. (JP) 1993-06-15 US disclosed
EP-0195311-B1 PROCESS FOR PREPARING FATTY ACID ESTERS NIPPON FINE CHEMICAL CO., LTD. (JP) 1990-06-27 EP disclosed
EP-0195311-A2 Process for preparing fatty acid esters NIPPON FINE CHEMICAL CO., LTD. (JP) 1986-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12611415-B2 Methods and compounds for treatment of metabolic disease SUCNR1, GPR119, SLC2A1 FFAR4 60/4885FFAR1 9/4885ALDH1A1 1173/4885
US-20220354963-A1 EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF EXOSC5, EXOSC4, EXOSC10 FFAR4 4548/4885FFAR1 4317/4885ALDH1A1 2475/4885
US-12594339-B2 Lipid prodrugs of JAK inhibitors and uses thereof JAK1, JAK3, JAK2 FFAR4 279/4885FFAR1 237/4885ALDH1A1 3461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.